[1. UDELSMAN R. ADRENAL. In: Norton A J, Bollinger RR, editors. Surgery, Basic Science and Clinical Evidence: Springer; 2001, p. 902.]Search in Google Scholar
[2. BULOW B, JANSSON S, JUHLIN C, STEEN L, THOREN M, WAHRENBERG H, et al. Adrenal incidentaloma – follow-up results from a Swedish prospective study. Eur J Endocrinol 2006; 154 (3):419-23.10.1530/eje.1.0211016498055]Search in Google Scholar
[3. ANAGNOSTIS P, KARAGIANNIS A, TZIOMALOS K, KAKAFIKA AI, ATHYROS VG, MIKHAILIDIS DP. Adrenal incidentaloma: a diagnostic challenge. Hormones (Athens) 2009; 8 (3):163-84.10.14310/horm.2002.123319671516]Search in Google Scholar
[4. GRUMBACH MM, BILLER BM, BRAUNSTEIN GD, CAMPBELL KK, CARNEY JA, GODLEY PA, et al. Management of the clinically inapparent adrenal mass (adrenal incidentaloma). Annals of Internal Medicine 2003; 138 (5):424-429.10.7326/0003-4819-138-5-200303040-0001312614096]Search in Google Scholar
[5. FASSNACHT M, ARLT W, BANCOS I, DRALLE H, NEWELL-PRICE J, SAHDEV A, et al. Management of adrenal incidentalomas: European society of endocrinology clinical practice guideline in collaboration with the European network for the study of adrenal tumors. European Journal of Endocrinology 2016; 175 (2):G1-G34.10.1530/EJE-16-046727390021]Search in Google Scholar
[6. PAPIERSKA L, CICHOCKI A, SANKOWSKI AJ, CWIKLA JB. Adrenal incidentaloma imaging - the first steps in therapeutic management. Pol J Radiol 2013; 78 (4):47-55.10.12659/PJR.889541390850724505223]Search in Google Scholar
[7. LINOS DA. Adrenal incidentaloma (adrenaloma). Hormones (Athens) 2003; 2 (1):12-21.10.14310/horm.2002.117817002998]Search in Google Scholar
[8. GEELHOED GW, DRUY EM. Management of the adrenal “incidentaloma”. Surgery 1982; 92 (5):866-74.]Search in Google Scholar
[9. GOVE PB. Webster’s third new international dictionary of the English language, unabridged: Merriam-Webster; 2002.]Search in Google Scholar
[10. FARRUGIA FA, MARTIKOS G, TZANETIS P, ZAVRAS N, CHARALAMPOPOULOS A, SOTIROPOULOS D, et al. Adrenal incidentaloma or epinephroma and review of the literature. Differential Diagnosis of Adrenal Incidentaloma. Khirurgiia 2016; October (3):120-129.]Search in Google Scholar
[11. DIVRY DBC. English-Greek and Greek English Handy Dictionary. In Revised Edition ed. New York: D.C. Divry, Inc., Publishers; 1994, p. 326.]Search in Google Scholar
[12. WARDA MHA, SHEHATA SM, ZAITON F. Chemical-shift MRI versus washout CT for characterizing adrenal incidentalomas. Clinical Imaging 2016; 40 (4):780-787.10.1016/j.clinimag.2016.02.00627317224]Search in Google Scholar
[13. YIP L, TUBLIN ME, FALCONE JA, NORDMAN CR, STANG MT, OGILVIE JB, et al. The adrenal mass: correlation of histopathology with imaging. Annals of surgical oncology 2010; 17 (3):846-852.10.1245/s10434-009-0829-219960266]Search in Google Scholar
[14. SEO JM, PARK BK, PARK SY, KIM CK. Characterization of lipid-poor adrenal adenoma: chemical-shift MRI and washout CT. American Journal of Roentgenology 2014; 202 (5):1043-1050.10.2214/AJR.13.1138924758658]Search in Google Scholar
[15. SCHIEDA N, SIEGELMAN ES. Update on CT and MRI of Adrenal Nodules. American Journal of Roentgenology 2017:1-12.10.2214/AJR.16.1775828225653]Search in Google Scholar
[16. ZEIGER MA, THOMPSON GB, DUH Q-Y, HAMRAHIAN AH, ANGELOS P, ELARAJ D, et al. American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons medical guidelines for the management of adrenal incidentalomas. Endocrine Practice 2009; 15:1-20.10.4158/EP.15.S1.1]Search in Google Scholar
[17. DEFECHEREUX T, DEGAUQUE C, HAMOIR E, LAMBERTY G, PREUD’HOMME L, MEURISSE M. [Discordance between actual and radiologically estimated size of an incidentaloma. Delay in questions regarding operative decision-making criteria]. Ann Chir 2002; 127 (2):126-9.10.1016/S0003-3944(01)00705-2]Search in Google Scholar
[18. PAPIERSKA L, CICHOCKI A, SANKOWSKI AJ, CWIKLA JB. Adrenal incidentaloma imaging – the first steps in therapeutic management. Pol J Radiol; 78 (4):47-55.10.12659/PJR.889541390850724505223]Search in Google Scholar
[19. REGINELLI A, DI GREZIA G, IZZO A, DΒ€™ANDREA A, GATTA G, CAPPABIANCA S, et al. Imaging of adrenal incidentaloma: Our experience. International Journal of Surgery 2014; 12:S126-S131.10.1016/j.ijsu.2014.05.02924862667]Open DOISearch in Google Scholar
[20. MORELLI V, SCILLITANI A, AROSIO M, CHIODINI I. Follow-up of patients with adrenal incidentaloma, in accordance with the European Society of Endocrinology guidelines: Could we be safe? Journal of Endocrinological Investigation 2016:1-3.10.1007/s40618-016-0558-x27744612]Search in Google Scholar
[21. CHIODINI I, ALBANI A, AMBROGIO AG, CAMPO M, DE MARTINO MC, MARCELLI G, et al. Six controversial issues on subclinical Cushing’s syndrome. Endocrine 2016:1-5.10.1007/s12020-016-1017-327406391]Search in Google Scholar
[22. CHIODINI I, MORELLI V. Subclinical hypercortisolism: how to deal with it? In: Cortisol Excess and Insufficiency: Karger Publishers; 2016, 28-38.10.1159/00044386227212038]Search in Google Scholar
[23. PAPIERSKA L, CICHOCKI A, SANKOWSKI AJ, CWIKLA JB. Adrenal incidentaloma imaging-the first steps in therapeutic management. Polish Journal of Radiology 2013; 78 (4):47.10.12659/PJR.889541]Search in Google Scholar
[24. MANTERO F, TERZOLO M, ARNALDI G, OSELLA G, MASINI AM, ALI A, et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab 2000; 85 (2):637-44.]Search in Google Scholar
[25. TABUCHI Y, OTSUKI M, KASAYAMA S, KOSUGI K, HASHIMOTO K, YAMAMOTO T, et al. Clinical and endocrinological characteristics of adrenal incidentaloma in Osaka region, Japan. Endocrine journal 2015 (0).]Search in Google Scholar
[26. SONG JH, GRAND DJ, BELAND MD, CHANG KJ, MACHAN JT, MAYO-SMITH WW. Morphologic features of 211 adrenal masses at initial contrast-enhanced CT: can we differentiate benign from malignant lesions using imaging features alone? American Journal of Roentgenology 2013; 201 (6):1248-1253.]Search in Google Scholar
[27. ILIAS I, SAHDEV A, REZNEK RH, GROSSMAN AB, PACAK K. The optimal imaging of adrenal tumours: a comparison of different methods. Endocrine-Related Cancer 2007; 14 (3):587-599.10.1677/ERC-07-004517914090]Search in Google Scholar
[28. DUNNICK NR, KOROBKIN M. Imaging of adrenal incidentalomas: current status. American Journal of Roentgenology 2002; 179 (3):559-568.10.2214/ajr.179.3.179055912185019]Search in Google Scholar
[29. LOCKHART ME, SMITH JK, KENNEY PJ. Imaging of adrenal masses. European journal of radiology 2002; 41 (2):95-112.10.1016/S0720-048X(01)00444-2]Open DOISearch in Google Scholar
[30. YOUNG JR WF. The incidentally discovered adrenal mass. New England Journal of Medicine 2007; 356 (6):601-610.10.1056/NEJMcp06547017287480]Search in Google Scholar
[31. ZEIGER MA, SIEGELMAN SS, HAMRAHIAN AH. Medical and surgical evaluation and treatment of adrenal incidentalomas. The Journal of Clinical Endocrinology & Metabolism 2011; 96 (7):2004-2015.10.1210/jc.2011-008521632813]Open DOISearch in Google Scholar
[32. MANSMANN G, LAU J, BALK E, ROTHBERG M, MIYACHI Y, BORNSTEIN SR. The clinically inapparent adrenal mass: update in diagnosis and management. Endocrine reviews 2004; 25 (2):309-340.10.1210/er.2002-003115082524]Open DOISearch in Google Scholar
[33. BEDNARCZUK T, BOLANOWSKI M, SWORCZAK K, GORNICKA B, CIESZANOWSKI A, OTTO M, et al. Adrenal incidentaloma in adults’ management recommendations by the Polish Society of Endocrinology. Endokrynologia Polska 2016; 67 (2):234.10.5603/EP.a2016.003927082051]Search in Google Scholar
[34. FRANCIS IR. Distinguishing benign from malignant adrenal masses. Cancer Imaging 2015; 3 (2):102.]Search in Google Scholar
[35. MAYO-SMITH W, LEE M, MCNICHOLAS M, HAHN P, BOLAND G, SAINI S. Characterization of adrenal masses (< 5 cm) by use of chemical shift MR imaging: observer performance versus quantitative measures. AJR. American Journal of Roentgenology 1995; 165 (1):91-95.10.2214/ajr.165.1.77856427785642]Search in Google Scholar
[36. BILBEY JH, MCLOUGHLIN R, KURKJIAN P, WILKINS G, CHAN N, SCHMIDT N, et al. MR imaging of adrenal masses: value of chemical-shift imaging for distinguishing adenomas from other tumors. AJR. American Journal of Roentgenology 1995; 164 (3):637-642.10.2214/ajr.164.3.78638857863885]Search in Google Scholar
[37. MIYAKE H, MAEDA H, TASHIRO M, SUZUKI K, NAGATOMO H, AIKAWA H, et al. CT of adrenal tumors: frequency and clinical significance of low-attenuation lesions. American Journal of Roentgenology 1989; 152 (5):1005-1007.10.2214/ajr.152.5.10052705336]Search in Google Scholar
[38. BLAKE MA, KRISHNAMOORTHY SK, BOLAND GW, SWEENEY AT, PITMAN MB, HARISINGHANI M, et al. Lowdensity pheochromocytoma on CT: a mimicker of adrenal adenoma. American Journal of Roentgenology 2003; 181 (6):1663-1668.10.2214/ajr.181.6.181166314627592]Search in Google Scholar
[39. ARNALDI G, MASINI A, GIACCHETTI G, TACCALITI A, FALOIA E, MANTERO F. Adrenal incidentaloma. Brazilian Journal of Medical and Biological Research 2000; 33 (10):1177-1189.10.1590/S0100-879X2000001000007]Search in Google Scholar
[40. LOU I, SCHNEIDER DF, LEVERSON GE, SIPPEL RS, CHEN H. Do additional imaging studies change operative management in patients undergoing adrenalectomy? Surgery 2015; 158 (4):1003-1011.]Search in Google Scholar
[41. NIH state-of-the-science statement on management of the clinically inapparent adrenal mass (“incidentaloma”). NIH Consens State Sci Statements 2002; 19 (2):1-25.]Search in Google Scholar
[42. BOLAND GW, BLAKE MA, HAHN PF, MAYO-SMITH WW. Incidental Adrenal Lesions: Principles, Techniques, and Algorithms for Imaging Characterization 1. Radiology 2008; 249 (3):756-775.10.1148/radiol.249307097619011181]Search in Google Scholar
[43. MAYO-SMITH WW, BOLAND GW, NOTO RB, LEE MJ. State-of-the-art adrenal imaging. Radiographics 2001; 21 (4):995-1012.10.1148/radiographics.21.4.g01jl2199511452074]Open DOISearch in Google Scholar
[44. LEE JK. Computed body tomography with MRI correlation: Lippincott Williams & Wilkins, 1998.]Search in Google Scholar
[45. KRESTIN GP, STEINBRICH W, FRIEDMANN G. Adrenal masses: evaluation with fast gradient-echo MR imaging and Gd-DTPA-enhanced dynamic studies. Radiology 1989; 171 (3):675-680.10.1148/radiology.171.3.27177372717737]Search in Google Scholar
[46. CONDER G, RENDLE J, KIDD S, MISRA RR. AZ of Abdominal Radiology. Cambridge University Press; 2009. p. 28-37.10.1017/CBO9780511575792]Search in Google Scholar
[47. SCHTEINGART D, DOHERTY G, GAUGER P, GIORDANO T, HAMMER G, KOROBKIN M, et al. Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocrine-Related Cancer 2005; 12 (3):667-680.10.1677/erc.1.0102916172199]Open DOISearch in Google Scholar
[48. ELSAYES KM, MUKUNDAN G, NARRA VR, LEWIS JR JS, SHIRKHODA A, FAROOKI A, et al. Adrenal Masses: MR Imaging Features with Pathologic Correlation 1. Radiographics 2004; 24 (suppl_1):S73-S86.10.1148/rg.24si04551415486251]Open DOISearch in Google Scholar
[49. FIEBRICH H-B, BROUWERS AH, KERSTENS MN, PIJL ME, KEMA IP, DE JONG JR, et al. 6-[F-18] Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with 123I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess. The Journal of Clinical Endocrinology & Metabolism 2009; 94 (10):3922-3930.10.1210/jc.2009-105419622618]Search in Google Scholar
[50. SUNDIN A. Imaging of adrenal masses with emphasis on adrenocortical tumors. Theranostics 2012; 2 (5):516-22.10.7150/thno.3613336455722737189]Search in Google Scholar
[51. Dorland. Dorland’s Illustrated Medical Dictionary. 32 ed: Saunders, 2007.]Search in Google Scholar
[52. LENDERS JW, PACAK K, WALTHER MM, LINEHAN WM, MANNELLI M, FRIBERG P, et al. Biochemical diagnosis of pheochromocytoma: which test is best? Jama 2002; 287 (11):1427-1434.]Search in Google Scholar
[53. IACOBONE M, CITTON M, SCARPA M, VIEL G, BOSCARO M, NITTI D. Systematic review of surgical treatment of subclinical Cushing’s syndrome. British Journal of Surgery 2015; 102 (4):318-330.10.1002/bjs.974225640696]Search in Google Scholar
[54. THOMAS AZ, BLUTE ML, SEITZ C, HABRA MA, KARAM JA. Management of the incidental adrenal mass. European Urology Focus 2016; 1 (3):223-230.10.1016/j.euf.2015.12.00628723391]Search in Google Scholar
[55. FUNDER JW, CAREY RM, FARDELLA C, GOMEZ-SANCHEZ CE, MANTERO F, STOWASSER M, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism 2008; 93 (9):3266-3281.10.1210/jc.2008-010418552288]Open DOISearch in Google Scholar
[56. CALHOUN DA, JONES D, TEXTOR S, GOFF DC, MURPHY TP, TOTO RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment. Circulation 2008; 117 (25):e510-e526.10.1161/CIRCULATIONAHA.108.18914118574054]Search in Google Scholar
[57. MATTSSON C, YOUNG WF. Primary aldosteronism: diagnostic and treatment strategies. Nature Clinical Practice Nephrology 2006; 2 (4):198-208.10.1038/ncpneph015116932426]Open DOISearch in Google Scholar
[58. YOUNG WF, JR. Minireview: primary aldosteronism--changing concepts in diagnosis and treatment. Endocrinology 2003; 144 (6):2208-13.10.1210/en.2003-027912746276]Search in Google Scholar
[59. YOUNG JR WF. Adrenalectomy for primary aldosteronism; authors’ reply. Ann Intern Med 2003; 138:157-159.10.7326/0003-4819-138-2-200301210-00024]Search in Google Scholar
[60. EISENHOFER G, LENDERS JW, LINEHAN WM, WALTHER MM, GOLDSTEIN DS, KEISER HR. Plasma normeta-nephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. New England Journal of Medicine 1999; 340 (24):1872-1879.10.1056/NEJM19990617340240410369850]Search in Google Scholar
[61. GALATI S-J, SAID M, GOSPIN R, BABIC N, BROWN K, GEER EB, et al. The mount Sinai clinical pathway for the management of pheochromocytoma. Endocrine Practice 2014; 21 (4):368-382.10.4158/EP14036.RA25297659]Open DOISearch in Google Scholar
[62. FRANCIS IR, GROSS MD, SHAPIRO B, KOROBKIN M, QUINT L. Integrated imaging of adrenal disease. Radiology 1992; 184 (1):1-13.10.1148/radiology.184.1.16090631609063]Search in Google Scholar
[63. FRANCIS IR, KOROBKIN M, BRODEUR FJ, YUTZY GG, QUINT LE, DUNNICK NR, et al. Pheochromocytoma Differentiation of adrenal adenomas from nonadenomas using CT attenuation values. Radiol Clin North Am 1996; 34 (6):1101-12.10.1016/S0033-8389(22)00693-5]Search in Google Scholar
[64. EISENHOFER G, GOLDSTEIN DS, WALTHER MM, FRIBERG P, LENDERS JW, KEISER HR, et al. Biochemical diagnosis of pheochromocytoma: how to distinguish true-from false-positive test results. The Journal of Clinical Endocrinology & Metabolism 2003; 88 (6):2656-2666.10.1210/jc.2002-03000512788870]Open DOISearch in Google Scholar
[65. VAN BERKEL A, LENDERS J, TIMMERS H. Diagnosis of endocrine Disease: Biochemical diagnosis of phaeochromocytoma and paraganglioma. European Journal of Endocrinology 2014; 170 (3):R109-R119.10.1530/EJE-13-088224347425]Search in Google Scholar
[66. MAUREA S, CUOCOLO A, REYNOLDS J, NEUMANN R, SALVATORE M. Diagnostic imaging in patients with paragangliomas. Computed tomography, magnetic resonance and MIBG scintigraphy comparison. The quarterly journal of nuclear medicine: official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR) 1996; 40 (4):365-371.]Search in Google Scholar
[67. RABER W, RAFFESBERG W, BISCHOF M, SCHEUBA C, NIEDERLE B, GASIC S, et al. Diagnostic efficacy of unconjugated plasma metanephrines for the detection of pheochromocytoma. Archives of Internal Medicine 2000; 160 (19):2957-2963.10.1001/archinte.160.19.295711041903]Search in Google Scholar
[68. MITTENDORF EA, EVANS DB, LEE JE, PERRIER ND. Pheochromocytoma: advances in genetics, diagnosis, localization, and treatment. Hematology/oncology clinics of North America 2007; 21 (3):509-525.10.1016/j.hoc.2007.04.01217548037]Open DOISearch in Google Scholar
[69. YOUNG WF. Primary aldosteronism: renaissance of a syndrome. Clinical endocrinology 2007; 66 (5):607-618.10.1111/j.1365-2265.2007.02775.x17492946]Search in Google Scholar
[70. SAWKA AM, JAESCHKE R, SINGH RJ, YOUNG JR WF. A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. The Journal of Clinical Endocrinology & Metabolism 2003; 88 (2):553-558.10.1210/jc.2002-02125112574179]Open DOISearch in Google Scholar
[71. JOHNSON PT, HORTON KM, FISHMAN EK. Adrenal Mass Imaging with Multidetector CT: Pathologic Conditions, Pearls, and Pitfalls 1. Radiographics 2009; 29 (5):1333-1351.10.1148/rg.29509502719755599]Open DOISearch in Google Scholar
[72. MARINI F, FALCHETTI A, DEL MONTE F, CARBONELL SALA S, TOGNARINI I, LUZI E, et al. Multiple endocrine neoplasia type 2. Orphanet J Rare Dis 2006; 1 (45):4.]Search in Google Scholar
[73. ERLIC Z, NEUMANN HP. Familial pheochromocytoma. Hormones (Athens) 2009; 8 (1):29-38.10.14310/horm.2002.121919269919]Search in Google Scholar
[74. National Institutes of Health Consensus Development Conference Statement: neurofibromatosis. Bethesda, Md., USA, July 13-15, 1987. Neurofibromatosis 1988; 1 (3):172-8.]Search in Google Scholar
[75. HERR K, MUGLIA VF, KOFF WJ, WESTPHALEN AC. Imaging of the adrenal gland lesions. Radiologia brasileira 2014; 47 (4):228-239.10.1590/0100-3984.2013.1762433712325741090]Search in Google Scholar
[76. BARZON L, SCARONI C, SONINO N, FALLO F, PAOLETTA A, BOSCARO M. Risk factors and long-term follow-up of adrenal incidentalomas. J Clin Endocrinol Metab 1999; 84 (2):520-6.10.1210/jc.84.2.520]Search in Google Scholar
[77. MORELLI V, REIMONDO G, GIORDANO R, DELLA CASA S, POLICOLA C, PALMIERI S, et al. Long-term follow-up in adrenal incidentalomas: an Italian multicenter study. The Journal of Clinical Endocrinology & Metabolism 2014; 99 (3):827-834.10.1210/jc.2013-352724423350]Search in Google Scholar
[78. LOPEZ D, LUQUE-FERNANDEZ MA, STEELE A, ADLER GK, TURCHIN A, VAIDYA A. “Nonfunctional” Adrenal Tumors and the Risk for Incident Diabetes and Cardiovascular Outcomes. A Cohort Study “Nonfunctional” Adrenal Tumors and Risk for Incident Diabetes. Annals of internal medicine 2016; 165 (8):533-542.10.7326/M16-0547545363927479926]Search in Google Scholar
[79. PAPANASTASIOU L, ALEXANDRAKI KI, ANDROULAKIS, II, FOUNTOULAKIS S, KOUNADI T, MARKOU A, et al. Concomitant alterations of metabolic parameters, cardiovascular risk factors and altered cortisol secretion in patients with adrenal incidentalomas during prolonged follow-up. Clin Endocrinol (Oxf); 86 (4):488-498.10.1111/cen.13294]Search in Google Scholar
[80. SALCUNI AS, MORELLI V, VAINICHER CE, PALMIERI S, CAIROLI E, SPADA A, et al. Adrenalectomy reduces the risk of vertebral fractures in patients with monolateral adrenal incidentalomas and subclinical hypercortisolism. European Journal of Endocrinology 2016; 174 (3):261-269.10.1530/EJE-15-0977]Search in Google Scholar
[81. TUNA MM, IMGA NN, DOGAN BA, YILMAZ FM, TOPCUOGLLU C, AKBABA G, et al. Non-functioning adrenal incidentalomas are associated with higher hypertension prevalence and higher risk of atherosclerosis. Journal of endocrinological investigation 2014; 37 (8):765-768.10.1007/s40618-014-0106-5]Search in Google Scholar
[82. YE Y-L, YUAN X-X, CHEN M-K, DAI Y-P, QIN Z-K, ZHENG F-F. Management of adrenal incidentaloma: the role of adrenalectomy may be underestimated. BMC surgery 2016; 16 (1):41.10.1186/s12893-016-0154-1]Search in Google Scholar
[83. FONTANA D, PORPIGLIA F, DESTEFANIS P, FIORI C, ALI A, TERZOLO M, et al. What is the role of ultrasonography in the follow-up of adrenal incidentalomas? Urology 1999; 54 (4):612-616.10.1016/S0090-4295(99)00226-5]Open DOISearch in Google Scholar
[84. MULATERO, P., RABBIA F, MILAN A, PAGLIERI C, MORELLO F, CHIANDUSSI L, VEGLIO F. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension 2002; 40 (6):897-902.10.1161/01.HYP.0000038478.59760.4112468576]Open DOISearch in Google Scholar